Your browser doesn't support javascript.
Gasdermin-D activation by SARS-CoV-2 triggers NET and mediate COVID-19 immunopathology.
Silva, Camila Meirelles S; Wanderley, Carlos Wagner S; Veras, Flavio Protasio; Gonçalves, Augusto Velozo; Lima, Mikhael Haruo Fernandes; Toller-Kawahisa, Juliana Escher; Gomes, Giovanni Freitas; Nascimento, Daniele Carvalho; Monteiro, Valter V Silva; Paiva, Isadora Marques; Almeida, Cícero José Luíz Ramos; Caetité, Diego Brito; Silva, Juliana Costa; Lopes, Maria Isabel Fernandes; Bonjorno, Letícia Pastorelli; Giannini, Marcela Cavichioli; Amaral, Natalia Brasil; Benatti, Maíra Nilson; Santana, Rodrigo Carvalho; Damasceno, Luis Eduardo Alves; Silva, Bruna Manuella Souza; Schneider, Ayda Henriques; Castro, Icaro Maia Santos; Silva, Juan Carlo Santos; Vasconcelos, Amanda Pereira; Gonçalves, Tiago Tomazini; Batah, Sabrina Setembre; Rodrigues, Tamara Silva; Costa, Victor Ferreira; Pontelli, Marjorie Cornejo; Martins, Ronaldo B; Martins, Timna Varela; Espósito, Danillo Lucas Alves; Cebinelli, Guilherme Cesar Martelossi; da Fonseca, Benedito Antônio Lopes; Leiria, Luiz Osório Silveira; Cunha, Larissa Dias; Arruda, Eurico; Nakaia, Helder I; Fabro, Alexandre Todorovic; Oliveira, Rene D R; Zamboni, Dario S; Louzada-Junior, Paulo; Cunha, Thiago Mattar; Alves-Filho, José Carlos Farias; Cunha, Fernando Queiroz.
  • Silva CMS; Center for Research in Inflammatory Diseases (CRID), Ribeirão Preto Medical School, University of São Paulo, Av. Bandeirantes 3900, Monte Alegre, Ribeirão Preto, São Paulo, 14049-900, Brazil.
  • Wanderley CWS; Department of Immunology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, São Paulo, Brazil.
  • Veras FP; Center for Research in Inflammatory Diseases (CRID), Ribeirão Preto Medical School, University of São Paulo, Av. Bandeirantes 3900, Monte Alegre, Ribeirão Preto, São Paulo, 14049-900, Brazil.
  • Gonçalves AV; Department of Pharmacology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, São Paulo, Brazil.
  • Lima MHF; Center for Research in Inflammatory Diseases (CRID), Ribeirão Preto Medical School, University of São Paulo, Av. Bandeirantes 3900, Monte Alegre, Ribeirão Preto, São Paulo, 14049-900, Brazil.
  • Toller-Kawahisa JE; Department of Pharmacology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, São Paulo, Brazil.
  • Gomes GF; Center for Research in Inflammatory Diseases (CRID), Ribeirão Preto Medical School, University of São Paulo, Av. Bandeirantes 3900, Monte Alegre, Ribeirão Preto, São Paulo, 14049-900, Brazil.
  • Nascimento DC; Department of Cell and Molecular Biology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, São Paulo, Brazil.
  • Monteiro VVS; Center for Research in Inflammatory Diseases (CRID), Ribeirão Preto Medical School, University of São Paulo, Av. Bandeirantes 3900, Monte Alegre, Ribeirão Preto, São Paulo, 14049-900, Brazil.
  • Paiva IM; Center for Research in Inflammatory Diseases (CRID), Ribeirão Preto Medical School, University of São Paulo, Av. Bandeirantes 3900, Monte Alegre, Ribeirão Preto, São Paulo, 14049-900, Brazil.
  • Almeida CJLR; Center for Research in Inflammatory Diseases (CRID), Ribeirão Preto Medical School, University of São Paulo, Av. Bandeirantes 3900, Monte Alegre, Ribeirão Preto, São Paulo, 14049-900, Brazil.
  • Caetité DB; Center for Research in Inflammatory Diseases (CRID), Ribeirão Preto Medical School, University of São Paulo, Av. Bandeirantes 3900, Monte Alegre, Ribeirão Preto, São Paulo, 14049-900, Brazil.
  • Silva JC; Department of Immunology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, São Paulo, Brazil.
  • Lopes MIF; Center for Research in Inflammatory Diseases (CRID), Ribeirão Preto Medical School, University of São Paulo, Av. Bandeirantes 3900, Monte Alegre, Ribeirão Preto, São Paulo, 14049-900, Brazil.
  • Bonjorno LP; Center for Research in Inflammatory Diseases (CRID), Ribeirão Preto Medical School, University of São Paulo, Av. Bandeirantes 3900, Monte Alegre, Ribeirão Preto, São Paulo, 14049-900, Brazil.
  • Giannini MC; Center for Research in Inflammatory Diseases (CRID), Ribeirão Preto Medical School, University of São Paulo, Av. Bandeirantes 3900, Monte Alegre, Ribeirão Preto, São Paulo, 14049-900, Brazil.
  • Amaral NB; Center for Research in Inflammatory Diseases (CRID), Ribeirão Preto Medical School, University of São Paulo, Av. Bandeirantes 3900, Monte Alegre, Ribeirão Preto, São Paulo, 14049-900, Brazil.
  • Benatti MN; Center for Research in Inflammatory Diseases (CRID), Ribeirão Preto Medical School, University of São Paulo, Av. Bandeirantes 3900, Monte Alegre, Ribeirão Preto, São Paulo, 14049-900, Brazil.
  • Santana RC; Divisions of Clinical Immunology, Emergency, Infectious Diseases, and Intensive Care Unit, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, São Paulo, Brazil.
  • Damasceno LEA; Divisions of Clinical Immunology, Emergency, Infectious Diseases, and Intensive Care Unit, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, São Paulo, Brazil.
  • Silva BMS; Divisions of Clinical Immunology, Emergency, Infectious Diseases, and Intensive Care Unit, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, São Paulo, Brazil.
  • Schneider AH; Divisions of Clinical Immunology, Emergency, Infectious Diseases, and Intensive Care Unit, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, São Paulo, Brazil.
  • Castro IMS; Divisions of Clinical Immunology, Emergency, Infectious Diseases, and Intensive Care Unit, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, São Paulo, Brazil.
  • Silva JCS; Divisions of Clinical Immunology, Emergency, Infectious Diseases, and Intensive Care Unit, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, São Paulo, Brazil.
  • Vasconcelos AP; Center for Research in Inflammatory Diseases (CRID), Ribeirão Preto Medical School, University of São Paulo, Av. Bandeirantes 3900, Monte Alegre, Ribeirão Preto, São Paulo, 14049-900, Brazil.
  • Gonçalves TT; Department of Immunology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, São Paulo, Brazil.
  • Batah SS; Center for Research in Inflammatory Diseases (CRID), Ribeirão Preto Medical School, University of São Paulo, Av. Bandeirantes 3900, Monte Alegre, Ribeirão Preto, São Paulo, 14049-900, Brazil.
  • Rodrigues TS; Department of Immunology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, São Paulo, Brazil.
  • Costa VF; Center for Research in Inflammatory Diseases (CRID), Ribeirão Preto Medical School, University of São Paulo, Av. Bandeirantes 3900, Monte Alegre, Ribeirão Preto, São Paulo, 14049-900, Brazil.
  • Pontelli MC; Department of Pharmacology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, São Paulo, Brazil.
  • Martins RB; Center for Research in Inflammatory Diseases (CRID), Ribeirão Preto Medical School, University of São Paulo, Av. Bandeirantes 3900, Monte Alegre, Ribeirão Preto, São Paulo, 14049-900, Brazil.
  • Martins TV; Department of Clinical and Toxicological Analysis, Faculty of Pharmaceutical Sciences, University of São Paulo, São Paulo, Brazil.
  • Espósito DLA; Center for Research in Inflammatory Diseases (CRID), Ribeirão Preto Medical School, University of São Paulo, Av. Bandeirantes 3900, Monte Alegre, Ribeirão Preto, São Paulo, 14049-900, Brazil.
  • Cebinelli GCM; Department of Clinical and Toxicological Analysis, Faculty of Pharmaceutical Sciences, University of São Paulo, São Paulo, Brazil.
  • da Fonseca BAL; Center for Research in Inflammatory Diseases (CRID), Ribeirão Preto Medical School, University of São Paulo, Av. Bandeirantes 3900, Monte Alegre, Ribeirão Preto, São Paulo, 14049-900, Brazil.
  • Leiria LOS; Department of Clinical and Toxicological Analysis, Faculty of Pharmaceutical Sciences, University of São Paulo, São Paulo, Brazil.
  • Cunha LD; Center for Research in Inflammatory Diseases (CRID), Ribeirão Preto Medical School, University of São Paulo, Av. Bandeirantes 3900, Monte Alegre, Ribeirão Preto, São Paulo, 14049-900, Brazil.
  • Arruda E; Department of Pathology and Legal Medicine, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, São Paulo, Brazil.
  • Nakaia HI; Center for Research in Inflammatory Diseases (CRID), Ribeirão Preto Medical School, University of São Paulo, Av. Bandeirantes 3900, Monte Alegre, Ribeirão Preto, São Paulo, 14049-900, Brazil.
  • Fabro AT; Department of Cell and Molecular Biology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, São Paulo, Brazil.
  • Oliveira RDR; Center for Research in Inflammatory Diseases (CRID), Ribeirão Preto Medical School, University of São Paulo, Av. Bandeirantes 3900, Monte Alegre, Ribeirão Preto, São Paulo, 14049-900, Brazil.
  • Zamboni DS; Department of Immunology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, São Paulo, Brazil.
  • Louzada-Junior P; Department of Cell and Molecular Biology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, São Paulo, Brazil.
  • Cunha TM; Virology Research Center of the Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, São Paulo, Brazil.
  • Alves-Filho JCF; Department of Cell and Molecular Biology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, São Paulo, Brazil.
  • Cunha FQ; Virology Research Center of the Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, São Paulo, Brazil.
Crit Care ; 26(1): 206, 2022 07 07.
Article in English | MEDLINE | ID: covidwho-1923570
ABSTRACT

BACKGROUND:

The release of neutrophil extracellular traps (NETs) is associated with inflammation, coagulopathy, and organ damage found in severe cases of COVID-19. However, the molecular mechanisms underlying the release of NETs in COVID-19 remain unclear.

OBJECTIVES:

We aim to investigate the role of the Gasdermin-D (GSDMD) pathway on NETs release and the development of organ damage during COVID-19.

METHODS:

We performed a single-cell transcriptome analysis in public data of bronchoalveolar lavage. Then, we enrolled 63 hospitalized patients with moderate and severe COVID-19. We analyze in blood and lung tissue samples the expression of GSDMD, presence of NETs, and signaling pathways upstreaming. Furthermore, we analyzed the treatment with disulfiram in a mouse model of SARS-CoV-2 infection.

RESULTS:

We found that the SARS-CoV-2 virus directly activates the pore-forming protein GSDMD that triggers NET production and organ damage in COVID-19. Single-cell transcriptome analysis revealed that the expression of GSDMD and inflammasome-related genes were increased in COVID-19 patients. High expression of active GSDMD associated with NETs structures was found in the lung tissue of COVID-19 patients. Furthermore, we showed that activation of GSDMD in neutrophils requires active caspase1/4 and live SARS-CoV-2, which infects neutrophils. In a mouse model of SARS-CoV-2 infection, the treatment with disulfiram inhibited NETs release and reduced organ damage.

CONCLUSION:

These results demonstrated that GSDMD-dependent NETosis plays a critical role in COVID-19 immunopathology and suggests GSDMD as a novel potential target for improving the COVID-19 therapeutic strategy.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Extracellular Traps / COVID-19 Drug Treatment Limits: Animals Language: English Journal: Crit Care Year: 2022 Document Type: Article Affiliation country: S13054-022-04062-5

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Extracellular Traps / COVID-19 Drug Treatment Limits: Animals Language: English Journal: Crit Care Year: 2022 Document Type: Article Affiliation country: S13054-022-04062-5